Idiosyncratic drug-induced liver injury: A clinical update

Current Gastroenterology Reports

Volumn 13, Issue 1, 2011, Pages 65-71

  Maddur, Haripriya ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug induced liver injury (DILI); Drug Induced Liver Injury Network (DILIN); Genome wide association studies

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANABOLIC AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ATOMOXETINE; BILIRUBIN; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; DICLOFENAC; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PLACEBO; TELITHROMYCIN; TUBERCULOSTATIC AGENT;

ACUTE LIVER FAILURE; ARTICLE; CLINICAL FEATURE; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PREDICTION; RISK FACTOR; SCORING SYSTEM; TOXIC HEPATITIS;

DRUG EVALUATION; DRUG-INDUCED LIVER INJURY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; RISK FACTORS;

EID: 79551525328     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0154-8     Document Type: Article

References (36)

1. AM Larson J Polson RJ Fontana, et al. 2005 Acetaminophen-induced acute liver failure: results of a United States multi-center, prospective study Hepatology 42 1364 1372 1:CAS:528:DC%2BD2MXhtlGns7rF 10.1002/hep.20948 16317692 (Pubitemid 43260039)
2. D Larrey 2002 Epidemiology and individual susceptibility to adverse drug reactions affecting the liver Semin Liver Dis 22 145 155 1:CAS:528: DC%2BD38XktlSjtr0%3D 10.1055/s-2002-30101 12016546 (Pubitemid 34496468)
3. N Chalasani RJ Fontana L Herbert, et al. 2008 Causes, clinical features, and outcomes from a prospective study of drug-Induced liver injury in the United States Gastroenterology 135 1924 1934 10.1053/j.gastro.2008.09.011 18955056 This paper reports preliminary findings of an ongoing study (nearly 800 patients enrolled) conducted in the United States. This study confirmed that DILI with jaundice carries high mortality. A surprising finding of this study is that about 0.5% of enrolled patients had unsuspected acute hepatitis C masquerading as DILI
4. RJ Andrade I Lucena C Fernandez, et al. 2005 Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period Gastroenterology 129 512 521 16083708
5. L Ibanez E Perez X Vidal JR Laporte 2002 Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs J Hepatol 37 592 600 10.1016/S0168-8278(02)00231-3 12399224 (Pubitemid 35305538)
6. V Alla J Abraham J Siddique, et al. 2006 Autoimmune liver disease triggered by statins: report of 3 instances and review of literature J Clin Gastroenterol 40 757 761 1:CAS:528:DC%2BD28XovVWjtb0%3D 10.1097/00004836- 200609000-00018 16940892 (Pubitemid 44350601)
7. JR Lim PR Fraught N Chalasani J Molleston 2006 Severe liver injury after starting atomoxetine (Strattera) in two children J Pediatrics 148 831 834 10.1016/j.jpeds.2006.01.035 (Pubitemid 43870084)
8. E Bjornsson J Talwalkar S Treeprasertsuk, et al. 2010 Drug induced Autoimmune Hepatitis: clinical characteristics and prognosis Hepatology 51 2040 2048 20512992
9. N Chalasani E Bjornsson 2010 Risk factors for idiosyncratic drug-induced liver injury Gastroenterology 138 2246 2259 1:CAS:528:DC%2BC3cXnslaku7c%3D 10.1053/j.gastro.2010.04.001 20394749 This recently published review article summarizes nongenetic and genetic risk factors for developing idiosyncratic DILI
10. N Chalasani 2005 Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease Hepatology 41 690 695 1:CAS:528: DC%2BD2MXjsV2ms7o%3D 10.1002/hep.20671 15789367 (Pubitemid 40462927)
11. D Cohen F Anania N Chalasani 2006 Report of the liver expert panel. Statin Safety Task Force, National Lipid Association Am J Cardiol 97 Suppl 77C 81C 1:CAS:528:DC%2BD28XkvF2gsrg%3D 10.1016/j.amjcard.2005.12.014 16581333
12. N Chalasani H Aljadhey J Kesterson, et al. 2004 Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity Gastroenterology 126 1287 1292 1:CAS:528:DC%2BD2cXksF2qtLw%3D 10.1053/j.gastro.2004.02.015 15131789 (Pubitemid 38552793)
13. R Vuppalanchi E Teal N Chalasani 2005 Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes Am J Med Sci 329 62 65 10.1097/00000441-200502000-00002 15711421 (Pubitemid 40250595)
14. G Targher CP Day E Bonor 2010 Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N Engl J Med 363 1341 1350 1:CAS:528:DC%2BC3cXht1Wqt7vO 10.1056/NEJMra0912063 20879883
15. JD Browning 2006 Statins and hepatic steatosis: perspectives from the Dallas Heart Study Hepatology 44 466 471 1:CAS:528:DC%2BD28XptVKmtLY%3D 10.1002/hep.21248 16871575 (Pubitemid 44214886)
16. M Nunez 2010 Clinical syndromes and consequences of antiretroviral- related hepatotoxicity Hepatology 52 1143 1155 1:CAS:528:DC%2BC3cXhtFyitr3N 10.1002/hep.23716 20812358
17. WB Park W Kim KL Lee, et al. 2010 Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis J Infect 61 323 329 10.1016/j.jinf.2010.07.009 20670648
18. J Uetrecht 2007 Idiosyncratic drug reactions: current understanding Annu Rev Pharmacol Toxicol 47 513 539 1:CAS:528:DC%2BD2sXit1altb0%3D 10.1146/annurev.pharmtox.47.120505.105150 16879083
19. C Lammert S Einarsson C Saha, et al. 2008 Relationship between daily dose of oral medications and idiosyncratic drug induced liver injury (DILI): search for signals Hepatology 47 2003 2009 1:CAS:528:DC%2BD1cXotVagt7w%3D 10.1002/hep.22272 18454504 This study showed that oral compounds administered at doses 50 mg/day are at higher risk to cause hepatotoxicity than those given at lower doses. This study consisted of several datasets that exhibited a similar pattern of dose-dependency (Pubitemid 351945567)
20. C Lammert A Niklasson E Bjornsson N Chalasani 2010 Oral medications with significant hepatic metabolism are at higher risk for hepatic adverse events Hepatology 51 615 620 1:CAS:528:DC%2BC3cXisVGnsr8%3D 19839004
21. JR Andrade MI Lucena N Kaplowitz, et al. 2006 Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry Hepatology 44 1581 1588 1:CAS:528:DC%2BD2sXislKrtQ%3D%3D 10.1002/hep.21424 17133470 (Pubitemid 44953663)
22. RJ Fontana PB Watkins HL Bonkovsky, et al. 2009 Rationale, design and conduct of the drug induced liver injury network prospective study Drug Safety 32 55 68 1:CAS:528:DC%2BD1MXjslaltb8%3D 10.2165/00002018-200932010-00005 19132805
23. E Björnsson E Kalaitzakis R Olsson 2007 The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury Aliment Pharmacol Ther 25 1411 1421 10.1111/j.1365-2036.2007.03330.x 17539980 (Pubitemid 46848886)
24. C Benichou 1990 Criteria of drug-induced liver disorders. Report of an international consensus meeting J Hepatol 11 272 276 1:STN:280: DyaK3M%2Fnt12gtQ%3D%3D 10.1016/0168-8278(90)90124-A 2254635
25. C Benichou G Danan A Falhault, et al. 1993 Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge J Clin Epidemiol 45 1331 1336 10.1016/0895-4356(93)90102-7 (Pubitemid 23333874)
26. DC Rockey LB Seeff J Rochon for the Drug-Induced Liver Injury Network, et al. 2010 A structured assessment process to assign causality in drug induced liver injury Hepatology 51 2117 2126 20512999
27. JI Papay D Clines R Rafi, et al. 2009 Drug-induced liver injury following positive drug rechallenge Regul Toxicol Pharmacol 54 84 90 1:CAS:528: DC%2BD1MXltlCjsrk%3D 10.1016/j.yrtph.2009.03.003 19303041
28. HR Dalton HJ Fellows W Stableforth, et al. 2007 The role of hepatitis E virus testing in drug-induced liver injury Aliment Pharmacol Ther 26 1429 1435 1:STN:280:DC%2BD2snlvVSrsw%3D%3D 10.1111/j.1365-2036.2007.03504.x 17850420 (Pubitemid 350045603)
29. N Kaplowitz 2005 Idiosyncratic drug hepatotoxicity Nat Rev Drug Discov 4 489 499 1:CAS:528:DC%2BD2MXks12ktro%3D 10.1038/nrd1750 15931258 (Pubitemid 40861991)
30. A Kindmark A Jawaid CG Harbron, et al. 2008 Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis Pharmacogenomics J 8 186 195 1:CAS:528:DC%2BD1cXmtVagsb0%3D 10.1038/sj.tpj.6500458 17505501 This article describes the first genome-wide association study conducted to explore the genetic basis of DILI in humans. Ximelagatran, a compound with great promise, was abandoned because of idiosyncratic DILI. This study showed a strong relationship between HLA DRB107 and HLA DQA102 and liver injury from ximelagatran (Pubitemid 351712643)
31. AK Daly PT Donaldson P Bhatnagar, et al. 2009 HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat Genet 41 816 821 1:CAS:528:DC%2BD1MXms1alu7o%3D 10.1038/ng.379 19483685 A landmark article published by the International SAE consortium showed an exceptionally strong relationship between HLA B5701 and flucloxacillin hepatotoxicity. This compound is not available in the United States
32. The International Serious Adverse Events Consortium DILI Genetics Research Update: Drug-induced liver injury getting the medicine and science together. Presented at the Food and Drug Administration/American Association for the Study of Liver Diseases/Pharmaceutical Research and Manufacturers of America (FDA/AASLD/PhRMA) meeting. Silver Spring, MD; March 24, 2010. Available at http://www.aasld.org/conferences/Documents/PresentationLibrary/ 2010Hepatoxicity-SessionII-Nelson.pdf. Accessed October 2010.
33. US Department of Health and Human Services, Food and Drug Administration: Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed October 2010.
34. E Bjornsson 2006 Drug induced liver injury: Hy's rule revisited Clin Pharmacol Ther 79 521 528 10.1016/j.clpt.2006.02.012 16765139 (Pubitemid 43817945)
35. JH Lewis 2006 Hy's law, the "rezulin rule", and other predictors of severe drug-induced hepatotoxicity; putting risk-benefit into perspective Pharmacoepidemiol Drug Saf 15 221 229 1:CAS:528:DC%2BD28XkvFGms74%3D 10.1002/pds.1209 16444771
36. WM Lee LS Hynan L Rossaro, et al. 2009 Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure Gastroenterology 137 856 864 1:CAS:528:DC%2BD1MXhtF2isrbJ 10.1053/j.gastro.2009.06.006 19524577